A realistic earliest FDA decision window, assuming Phase 3 confirms the Phase 2 findings, is 2028
For those who can't afford to contribute right now, please sign up for our free Watchdog Update newsletters, & help the spread word about the Sentinel to your friends, family, neighbors & co-workers
Data sharing is not applicable to this article
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes
GLP-1s, first approved for type 2 diabetes in 2005, lower blood glucose, help avoid fatty liver disease, and help with obesity-related problems such as knee pain, sleep apnea, and gastroesophageal reflux
Because GLP-1 medications reduce appetite and food intake, prioritizing protein is essential, not optional